Publications
Detailed Information
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Kim, Areumnuri | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.contributor.author | Park, Sunhoo | - |
dc.contributor.author | Kim, Dong Wan | - |
dc.contributor.author | Lee, Seung-Sook | - |
dc.date.accessioned | 2020-04-27T11:21:00Z | - |
dc.date.available | 2020-04-27T11:21:00Z | - |
dc.date.created | 2018-10-29 | - |
dc.date.issued | 2015-08 | - |
dc.identifier.citation | Cancer Letters, Vol.364 No.2, pp.89-97 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.other | 63798 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165372 | - |
dc.description.abstract | We investigated the role of the histone deacetylase inhibitor, romidepsin, in Epstein Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL), an aggressive non-Hodgkin lymphoma with poor clinical outcomes. We used EBV-positive and EBV-negative DLBCL cell lines and generated two EBV-transfected cell lines, LY7/EBV and U2932/EBV. Romidepsin was cytotoxic to cultured EBV-positive cells via the activation of the caspase cascade. Moreover, in vivo mice xenograft models demonstrated the cytotoxicity of romidepsin to EBV-positive DLBCL cells. Romidepsin induced cytotoxicity via the reduction of LMP1 and c-myc expression in EBV-positive cells. Inhibiting either LMP1 or c-myc using small inhibitory RNAs caused partial cytotoxicity in EBV-positive Farage and U2932/EBV lines. The dual inhibition of LMP1 and c-myc showed a synergistic cytotoxic effect in EBV-positive cells similar in magnitude to that of romidepsin alone. In addition, either double blockade of LMP1 and c-myc activity or romidepsin single treatment activated EBV lytic cycle in EBV-positive cells. In conclusion, romidepsin exerts strong anti-tumor activity in EBV-positive DLBCL via the inhibition of both LMP1 and c-myc. Our findings indicate that romidepsin might be a promising treatment for EBV-positive DLBCL. (C) 2015 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1016/j.canlet.2015.03.016 | - |
dc.citation.journaltitle | Cancer Letters | - |
dc.identifier.wosid | 000357140400001 | - |
dc.identifier.scopusid | 2-s2.0-84930090247 | - |
dc.citation.endpage | 97 | - |
dc.citation.number | 2 | - |
dc.citation.startpage | 89 | - |
dc.citation.volume | 364 | - |
dc.identifier.sci | 000357140400001 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EPSTEIN-BARR-VIRUS | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | NASOPHARYNGEAL CARCINOMA | - |
dc.subject.keywordPlus | DEPSIPEPTIDE FR901228 | - |
dc.subject.keywordPlus | CANCER-CELLS | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | TRANSFORMATION | - |
dc.subject.keywordAuthor | c-myc | - |
dc.subject.keywordAuthor | Diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | Epstein-Barr virus | - |
dc.subject.keywordAuthor | Latent membrane protein-1 | - |
dc.subject.keywordAuthor | Romidepsin | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.